PGEN
NASDAQ · Biotechnology
Precigen Inc
$7.13
+0.22 (+3.18%)
Open$7.06
Previous Close$6.91
Day High$7.14
Day Low$6.95
52W High$7.23
52W Low$1.70
Volume—
Avg Volume6.46M
Market Cap2.60B
P/E Ratio—
EPS$-0.66
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+917.8% upside
Current
$7.13
$7.13
Target
$72.57
$72.57
$43.64
$72.57 avg
$99.14
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 11.25M | 15.81M | 411.38M |
| Net Income | -291,540,101 | -368,830,602 | -34,816,902 |
| Profit Margin | -2,588.2% | -2,458.8% | -8.5% |
| EBITDA | -124,836,539 | -166,706,089 | -49,679,638 |
| Free Cash Flow | — | — | -21,385,787 |
| Rev Growth | -28.9% | -28.9% | +17.8% |
| Debt/Equity | 4.46 | 4.46 | 0.95 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |